A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Crizotinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
- Indications Anaplastic large cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 Jun 2019 Planned primary completion date changed from 31 Jan 2021 to 31 Mar 2021.
- 04 Apr 2019 Planned primary completion date changed from 31 Dec 2021 to 31 Jan 2021.
- 11 Feb 2019 Status changed from recruiting to suspended.